{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:15:44Z","timestamp":1783149344765,"version":"3.54.6"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000774","name":"The University of Newcastle","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paediatric obstructive hypertrophic cardiomyopathy (oHCM) is a rare inherited cardiac disease that may present from childhood through adolescence and is associated with substantial long-term morbidity and mortality. Its management is based largely on observational studies and clinical experience and currently focusses on symptom improvement through medical therapy and, when indicated, septal reduction therapy to alleviate left ventricular outflow tract (LVOT) obstruction. In adult oHCM, mavacamten has established cardiac myosin inhibition as an effective strategy to reduce LVOT obstruction, but paediatric trial evidence has been lacking. The SCOUT-HCM trial is the first randomised placebo-controlled trial in adolescents to investigate the efficacy and safety of mavacamten for symptomatic oHCM. Among 44 adolescents (mean age 14.7\u2009\u00b1\u20091.7 years) mavacamten significantly reduced Valsalva-provoked LVOT gradients at 28 weeks, confirming short-term physiological efficacy. Secondary and exploratory findings, including NYHA functional class, cardiac structure and biomarkers, showed a trend to improvement, without a signal of left ventricular systolic dysfunction. The positive results of SCOUT-HCM, align with larger and longer adult oHCM trials and are likely to influence clinical practice, supporting a cautious integration of mavacamten in adolescent oHCM management. Longer follow-up and broader paediatric studies should determine durability of benefit, validated patient-reported outcomes, exercise capacity, arrhythmia burden, long-term safety and the need for septal reduction therapy in paediatric oHCM.<\/jats:p>","DOI":"10.1007\/s10741-026-10655-x","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:24:24Z","timestamp":1783146264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mavacamten in adolescent obstructive hypertrophic cardiomyopathy: SCOUTing a way forward"],"prefix":"10.1007","volume":"31","author":[{"given":"Joshua D.","family":"Bennetts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doan T. M.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljash","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Santner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"23","key":"10655_CR1","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM et al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 149(23):e1239\u2013e1311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250","journal-title":"Circulation"},{"issue":"37","key":"10655_CR2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"key":"10655_CR3","doi-asserted-by":"publisher","first-page":"708679","DOI":"10.3389\/fped.2021.708679","volume":"9","author":"G Norrish","year":"2021","unstructured":"Norrish G, Field E, Kaski JP (2021) Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere. Front Pediatr 9:708679 (Review) (In English). https:\/\/doi.org\/10.3389\/fped.2021.708679","journal-title":"Front Pediatr"},{"issue":"20","key":"10655_CR4","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","volume":"42","author":"NA Marston","year":"2021","unstructured":"Marston NA, Han L, Olivotto I et al (2021) Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J 42(20):1988\u20131996. https:\/\/doi.org\/10.1093\/eurheartj\/ehab148","journal-title":"Eur Heart J"},{"issue":"1","key":"10655_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.hfc.2021.07.012","volume":"18","author":"G Norrish","year":"2022","unstructured":"Norrish G, Kaski JP (2022) The risk of sudden death in children with hypertrophic cardiomyopathy. Heart Fail Clin 18(1):9\u201318. https:\/\/doi.org\/10.1016\/j.hfc.2021.07.012","journal-title":"Heart Fail Clin"},{"key":"10655_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.632293","volume":"9","author":"E Monda","year":"2021","unstructured":"Monda E, Rubino M, Lioncino M et al (2021) Hypertrophic cardiomyopathy in children: pathophysiology, diagnosis, and treatment of non-sarcomeric causes. Front Pediatr 9:632293. https:\/\/doi.org\/10.3389\/fped.2021.632293","journal-title":"Front Pediatr"},{"issue":"17","key":"10655_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.033767","volume":"13","author":"AT Owens","year":"2024","unstructured":"Owens AT, Desai M, Wheeler MT et al (2024) Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response. J Am Heart Assoc 13(17):e033767. https:\/\/doi.org\/10.1161\/JAHA.124.033767","journal-title":"J Am Heart Assoc"},{"key":"10655_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-026-10603-9","author":"A Grupper","year":"2026","unstructured":"Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K (2026) Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-026-10603-9","journal-title":"Heart Fail Rev"},{"key":"10655_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2601103","author":"JW Rossano","year":"2026","unstructured":"Rossano JW, Canter C, Wolf CM et al (2026) Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2601103","journal-title":"N Engl J Med"},{"issue":"19","key":"10655_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/circulationaha.124.072445","volume":"151","author":"MY Desai","year":"2025","unstructured":"Desai MY, Wolski K, Owens A et al (2025) Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation 151(19):1378\u20131390. https:\/\/doi.org\/10.1161\/circulationaha.124.072445","journal-title":"Circulation"},{"issue":"20","key":"10655_CR11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390(20):1849\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2401424","journal-title":"N Engl J Med"},{"issue":"10253","key":"10655_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(20)31792-x","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/s0140-6736(20)31792-x","journal-title":"Lancet"},{"issue":"1","key":"10655_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10741-025-10578-z","volume":"31","author":"K Hosseini","year":"2025","unstructured":"Hosseini K, Kazemian S, Harikrishnan S et al (2025) Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial. Heart Fail Rev 31(1):16. https:\/\/doi.org\/10.1007\/s10741-025-10578-z","journal-title":"Heart Fail Rev"},{"key":"10655_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd12100374","author":"C Menzies","year":"2025","unstructured":"Menzies C, Dolinsky VW (2025) Rethinking childhood-onset hypertrophic cardiomyopathy: a review of molecular mechanisms and unique therapy considerations. J Cardiovasc Dev Dis. https:\/\/doi.org\/10.3390\/jcdd12100374","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"10655_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.125.013418","volume":"19","author":"JP Kaski","year":"2026","unstructured":"Kaski JP, Kantor PF, Nakano SJ et al (2026) Efficacy and safety of aficamten in children and adolescents with obstructive hypertrophic cardiomyopathy: study design and rationale of CEDAR-HCM. Circ Heart Fail 19(2):e013418. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.125.013418","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10655_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.athoracsur.2023.04.021","volume":"116","author":"EM Griffeth","year":"2023","unstructured":"Griffeth EM, Dearani JA, Schaff HV et al (2023) Septal myectomy outcomes in children and adolescents with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 116(3):499\u2013507. https:\/\/doi.org\/10.1016\/j.athoracsur.2023.04.021","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"10655_CR17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/jcph.2298","volume":"63","author":"M Chiang","year":"2023","unstructured":"Chiang M, Sychterz C, Gaohua L et al (2023) Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model. J Clin Pharmacol 63(11):1275\u20131282. https:\/\/doi.org\/10.1002\/jcph.2298","journal-title":"J Clin Pharmacol"},{"key":"10655_CR18","doi-asserted-by":"publisher","unstructured":"Ricci F, Molinari LV, Mansour D et al (2025) Managing drug-drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants. Heart Rhythm 22(2):510\u2013525. https:\/\/doi.org\/10.1016\/j.hrthm.2024.11.041","DOI":"10.1016\/j.hrthm.2024.11.041"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10655-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10655-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:24:25Z","timestamp":1783146265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10655-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10655"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10655-x","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}